Arialys Therapeutics announced it raised $14.8 Million in an initial filing from an offering of $24.8 Million

Company

Location

About

Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain, aiming to expand treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. Founded to explore the latest discoveries in autoimmune neuropsychiatry, the company is advancing a novel approach based on the growing understanding that immune cells—not only in the body’s periphery but especially in the brain—can produce autoantibodies that cause severe neurological and psychiatric conditions.